Abstract. A single-chain 55,000-mol wt form of urokinase (UK), similar to that previously isolated from urine, was purified from a transformed kidney cell culture medium and characterized; and its fibrinolytic properties were evaluated. The preparation immunoprecipitated with UK antiserum, had a low intrinsic amidolytic activity that was 0.1% of its active derivative, and resisted diisopropyl fluorophosphate treatment and inactivation by plasma inhibitors. The single-chain UK was therefore designated pro-UK. In
Introduction
The discovery (1, 2) in this laboratory of a single chain, 55,000-mol wt form of urokinase (UK)' in human urine motivated a search for a more plentiful source to permit studies of its enzymatic and thrombolytic properties. A transformed human kidney cell culture developed by Collaborative Research Inc. (Lexington, MA) was found to meet this requirement. Since the single-chain UK purified from this cell culture medium proved to be a zymogen precursor of 55,000-mol wt two-chain UK (TC-UK), it was designated pro-UK.
In this study, the zymogenic properties of pro-UK were characterized, and its fibrinolytic effect was compared with UK in vitro and in two animal species.
Methods

Material
The pro-UK was purified by a modification of the method of Wun et al. (3) , by Collaborative Research Inc. from the spent tissue culture medium of a transformed human kidney cell line. TC-UK was obtained from Breon Laboratories, New York, (Breokinase) and from Serono Laboratories (Randolph, MA). A low molecular weight UK (LMW-UK) was obtained from Abbott Laboratories, Chicago, IL (Abbokinase). The reference standard for UK assays was a sample of the International Reference Preparation of Human UK (coded 66/46) obtained from The National Institute of Biological Standards and Control, London. Antisera to urinary and to tissue culture UK were obtained from Collaborative Research Inc.
Stock citrated plasma was obtained from the Red Cross, Boston, MA. Three individual units were pooled and stored in aliquots at -20'C. Fresh plasma was prepared from blood collected into EDTA obtained from six volunteers. Plasminogen was purified on Lysine-Sepharose (Pharmacia, Upsalla, Sweden) essentially by the method of Deutsch and Mertz (4) from diisopropyl fluorophosphate (DFP)-treated fresh plasma. Fibrinogen solutions were depleted of plasminogen by passage over a similar Lysine-Sepharose column.
A crude preparation of bovine thrombin, Thrombostat, was obtained from Parke-Davis, Morris Plains, NJ. Highly purified human thrombin was obtained from Collaborative Research Inc. Purified human fibrinogen was a product of Kabi Diagnostics (Stockholm, Sweden). Bovine trypsin and human plasmin were obtained from Sigma Chemical Co. (St. Louis, MO).
Procedures
Protein was measured by the method ofLowry et al. (5) . Sodium dodecyl sulfate (SDS) gel electrophoresis was performed by the method of Laemmli (6) using a 12.5% polyacrylamide gel. Samples were prepared either with or without 10 mM dithiothreitol (DTT). Gels were silver stained (7) or autoradiographed after drying, using Kodak X-Omat R film.
Urokinase was labeled with 125I via the lactoperoxidase reaction using immobilized lactoperoxidase/glucose oxidase (Enzymobeads, Bio-Rad Laboratories, Richmond, CA). 100 Mg of UK in 0.2 M sodium phosphate, pH 7.2, was reacted with 50 ul enzymobeads suspension, 10 Ml (1 mCi) Na '25I (New England Nuclear, Boston, MA), and 25 gl 1% l-D-glucose for 15 min at room temperature. Free iodine was separated on a column of Sephadex G-10 in 50 mM sodium phosphate, 0.1 M NaCl, pH 7.2. Fractions containing the iodinated protein were supplemented with human serum albumin to -100 Mg/ml. Resulting specific activity of the pro-UK was -3 MCi/Mg.
Immunoprecipitations were performed by the method of Kessler (8) using Staphylococcus aureus cells obtained from Calbiochem-Behring Corp., San Diego, CA (Pansorbin). Samples containing an estimated 200-500 ng UK were precipitated with 10 Ml of antiserum against urinary UK.
'25l-labeled pro-UK (17 Mg/ml) was treated with 28 Mig/ml trypsin, 1 National Institutes ofHealth (NIH) unit/ml ofcrude bovine thrombin (Parke-Davis Thrombostat), or I NIH unit/ml of purified human thrombin (Collaborative Research Inc.) by incubation for I h at 37°C. The products were analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) and autoradiography. To measure degradation by plasmin, unlabeled pro-UK (20,000 IU/ml final concentration) was mixed with plasminogen (10 Mg/ml) on ice. An aliquot was removed within 1 min and added to SDS-sample buffer containing 10 mM 2-mercaptoethanol and boiled. The remaining reaction mixture was raised to 37°C and incubated for 20 min, then sampled for electrophoresis. An SDS gel comparing these products with unincubated pro-UK was silver stained.
The standard fibrin plate assay of Brakman (9) was used to determine fibrinolytic activity of UK. Activities were measured in International Units (IU) relative to the International Reference Preparation as a primary standard. For measurement of pro-UK, fibrin-plates were enriched with plasminogen (0.2 mg/ml) in order to achieve full activation of the zymogen. Under these conditions, a specific activity of 100,000 IU/mg was obtained.
Amidolytic assays were performed as described in the product insert of the substrate S-2444 (Kabi Diagnostics). To measure activation, pro-UK (5,000 IU/ml) was incubated with or without plasminogen (20 ,ug/ ml) at 370C for 20 min in 50 mM Tris, 38 mM NaCl, pH 8.8. At 0, 5, 10, and 20 min of incubation, aliquots were drawn from each incubation tube and assayed for amidolytic activity using the UK specific chromogenic substrate, S-2444.
For DFP treatment, pro-UK and TC-UK were diluted, respectively, to 0.1 mg/ml (18 MM) in 0.1 M Hepes (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) pH 7.2, 0.3 mg/ml bovine albumin, 0.15 M NaCl. DFP was diluted into dimethylformamide to a stock concentration of 20 mM. Treatment was done at 20, 50, and 75 MM DFP on ice for 16 h. After this reaction period imidazole was added (10 mM), and the solutions were raised to room temperature for 2 h to catalyze the hydrolysis of remaining DFP, then stored on ice for 48 h.
Clot lysis '25I-labeled clots were prepared from human plasma (bank or fresh). Plasma (0.5 ml) plus -1.5 MCi 1251-fibrinogen (human fibrin, Ibrin; Amersham Corp., Arlington Heights, IL) (0.01 ml) was clotted with thromboplastin (Sigma Chemical Co.), 10 Ml, in the presence of 5 Ml CaCl2 (1 M). The clots were formed in 5-mm (i.d.) glass tubing, incubated 30 min (370C), and kept overnight at room temperature before transferring to a test tube.
(a) Pro-UK, TC-UK, or LMW-UK were incubated (370C, 4-6 h) in the presence of plasma (4 ml) or in buffer (phosphate-buffered saline, pH 7.4) containing fibrinogen (3 mg/ml) and plasminogen (0.2 mg/ml). Incubation was carried out with and without radiolabeled clots. At intervals, samples of the incubation medium were removed for measurement of radioactivity. Fibrinogen concentrations were determined at 0 and 4-6 h in aliquots to which aprotinin (1,000 KIU/ml final concentration) was added. Each experiment was done at least three times.
(b) Pro-UK (40 IU/ml) or TC-UK or LMW-UK (500 IU/ml) were preincubated (37°C) in fresh or bank plasma for 0, 2, 24, and 50 h before the addition of a radiolabeled clot and then incubated for an additional 6 h. Plasmin activity (using Kabi Diagnostics S2251) and fibrinogen were measured just before the clots were added.
(c) Radiolabeled clots that were made from human or homologous animal plasma were incubated in the plasma prepared from the following species: man, rhesus monkey, baboon, dog, rabbit, cat, horse, and pig. A species-sensitivity index to human UK and pro-UK was calculated by taking the reciprocal ofthe following product based on average figures from several experiments: hours X units needed to achieve complete clot lysis X 0.001. 15-30 min after embolization, a blood sample (4 ml) was collected into EDTA for baseline measurements. After this, an infusion of UK or of an equivalent volume of saline was started and continued for 5 h in rabbits and 6 h in dogs. Blood samples were collected after 30 min and then at hourly intervals for measurement of blood radioactivity (counts per minute per milliliter ofwhole blood), fibrinogen concentration and fibrinolytic activity. The latter was determined by spotting plasma on a standard fibrin plate. Corrections were made for the damping effect of plasma inhibitors from a curve of the fibrin plate lysis areas plotted against a range of concentrations of pro-UK added to dog or rabbit plasma.
At the end of each experiment, the rabbits were killed with an intravenous injection of sodium pentobarbital plus heparin (500-1,000 U). The heart and lungs were removed together and rinsed thoroughly in running tap water. The right heart and pulmonary vascular tree were carefully dissected and any residual clot was removed. The lungs were then cut into pieces and their radioactivity was counted. The sum of the radioactivity in the clot and lung was subtracted from the initial clot radioactivity (minus 15% for nonclottable radioactivity) to obtain the percentage clot lysis.
In dogs, the total amount of radioactivity administered (minus 15%) was divided by the dog's blood volume (100 ml/kg). This figure was divided by three to correct for extravascular distribution. The resultant figure was taken to represent the maximum achievable radioactivity per milliliter of blood, or 100% clot lysis. The percentage clot lysis based on the blood radioactivity was calculated from this figure.
Formulation and administration of UK. Lyophilized pro-UK was formulated in acetate-buffered saline (pH 4.8) in vials containing 1 mg of the proenzyme and reconstituted in albumin (0.2 mg/ml). The TC-UK and LMW-UK were formulated and reconstituted according to the manufacturer's instructions just before administration. Determination of dosage was based in the case of TC-UK and LMW-UK on the manufacturer's label. For pro-UK, dosage was determined in milligrams. For comparison with TC and LMW-UK, 1 mg of pro-UK was taken to be equivalent to 100,000 IU (assuming full activation).
Infusions were given through a marginal ear vein in the rabbit and a peripheral vein in the dog at a constant rate of 3 ml/h with an infusion pump. Bolus injections were administered by the same route over 30-60 s in a total volume of 5 ml.
Urokinase in rabbits. After embolization, the surviving rabbits were divided into the following groups: a saline control group (three rabbits) and three pairs of treatment groups which were given bolus injections and/or infusions of 100,000 IU/h or 200,000 IU/h for 5 h of either pro-UK or TC-UK (Table I ).
In the pro-UK-treated rabbits, the initial bolus was omitted, as it was found in preliminary experiments not to be necessary.
Urokinase in dogs. To evaluate clearance of activator activity and thrombolytic effect, a range ofbolus injections (intravenous) and infusions were given. One dog was given bolus injections (intravenous) only of pro-UK: 300,000, 400,000, and 800,000 IU (1 h between each bolus). Two dogs were given 300,000 IU of either TC-UK or LMW-UK, and I h later received 400,000 IU. Three dogs were given a bolus injection of pro-UK, 150,000 IU, followed by 75,000 IU/h for 6 h. One dog was given an equivalent dose of LMW-UK and three others were given 150,000 IU of LMW-UK followed by 100,000 IU/h. Three dogs were given infusions of saline in an equivalent volume.
Determination of t,12 for pro-UK. '25I-labeled pro-UK, which was 80% single chain by autoradiography of a reducing SDS-polyacrylamide gel, was injected into one dog (6 X 107 cpm) and two rabbits (1.5 X 106 cpm) and the blood radioactivity was followed.
Statistical analysis
The paired t test was used for all calculations.
Results
The single-chain nature of the tissue culture UK was apparent from its resistance to reduction by DTT to the separate light (22,000 mol wt) and heavy (33,000 mol wt) chain subunits of conventional TC-UK (55,000 mol wt). (Fig. 1) .
The immuno-identity of pro-UK with other UK was confirmed by quenching ofthe fibrin plate activity by UK-antiserum as well as by immunoprecipitation of radiolabeled pro-UK. On SDS-PAGE, the pro-UK gave an immunoprecipitant band at 55,000 mol wt, which resisted reduction by DTT.
Incubation of pro-UK with plasmin(ogen) induced degradation to subunits of 33,000 and 23,000 mol wt characteristic ofTC-UK. This seemed to occur rapidly as seen by the extensive degradation already present in the initial samples incubated for <1 min at 00C (Fig. 2 ). Among other agents tested, trypsin also caused a similar degradation of pro-UK as did bovine thrombin (Parke-Davis Thrombostat). However, since highly purified human thrombin had no such effect, this was attributed to contaminants in the bovine thrombin.
Incubation of 125I-labeled pro-UK in plasma under conditions of clotting and clot lysis showed conversion to TC-UK with the latter but not the former. The appearance of higher molecular weight bands, believed to represent inhibitor complexes with TC-UK, were also seen (Fig. 3, lane 2) . The essential features of the autoradiograph are apparent despite some baseline degradation of pro-UK to TC-UK which occurred during radioisotope labeling. The quality of protein banding was compromised by the overloading of the gel which was necessary for the detection of radioactivity (Fig. 3) .
The amidolytic activity of pro-UK was stimulated by incubation with plasmin under conditions that had been shown to cause conversion to the two-chain form. Amidolytic activity of pro-UK increased with time of incubation, while the activity of TC-UK was unaffected by plasmin. A 10-fold increase in amidolytic activity of pro-UK after plasmin incubation was seen, consistent with an -10% contamination by TC-UK (Fig. 4) . By a standard fibrin plate assay, the specific activity of pro-UK was measured in a range of 30,000-50,000 IU/mg. This is in contrast to a specific activity for TC-UK of 104,000 IU/mg (10) . However, when extra plasminogen was added to the formulation of the fibrin plates, the apparent activity or specific Hours Hours activity relative to the standard was increased. An asymptotic increase to a maximum of 100,000 IU/mg was found as the plasminogen concentration in the fibrin plate was increased from 0.01 to 0.2 mg/ml. At the normal median concentration in plasma (0.2 mg/ml), a maximum response was reached.
In vitro clot lysis studies IN PLASMA. Pro-UK induced complete clot lysis in 2-6 h, the rate and extent of which was dose-dependent over a range of 25-100 IU/ml. At the lower concentrations, an initial lag phase was followed by progressive lysis which invariably went to completion if the time of incubation was extended sufficiently. No significant differences in clot lysis were observed between experiments done with either fresh or bank plasma (Fig. 5 A) . In the six individual plasmas tested, 50 IU/ml of pro-UK induced a range of clot lysis with an average variation in lytic response at hourly intervals of -25%. TC-UK and LMW-UK were much less effective under the same experimental conditions even at 10-fold higher concentrations. The individual response was highly variable with 50% clot lysis occurring at concentrations ranging from 200 to 1,000 IU/ml and 100% clot lysis occurring in a range of 500-1,500 IU/ml. In contrast to pro-UK, the initial lysis rate with TC-UK or LMW-UK was rapid and then leveled off after the first 1-2 h with little additional lysis occurring after this period of time.
No differences between the effects of TC-UK and LMW-UK were found (Fig. 5 B) .
Pro-UK incubated in plasma without a clot caused no fibrinogenolysis and remained stable for long periods (see below). Furthermore, by autoradiography of SDS-gels '25I-pro-UK did not form inhibitor complexes (data not shown). In the presence of a clot, complete lysis was induced without any degradation (Fig.  7) . No detectable plasmin activity was present and no fibrinogen degradation had occurred at the time the clots were added to the incubation mixture. By contrast, TC-UK and LMW-UK lost fibrinolytic activity within a few minutes of incubation in plasma.
CLOT LYSIS IN PLASMA FROM VARIOUS MAMMA-LIAN SPECIES. A wide range of resistance to human UK in heterologous species was found. The two primates had a sensitivity index closest to that of man. In each case, the sensitivity index was 5-10-fold greater for pro-UK than for TC-UK. No differences in lysis rates between clots made from human or homologous animal plasma were found in these experiments (Table I) .
Animal studies
RABBITS. There was a 50% mortality associated with embolization, which occurred within 5 min of embolization. Animals who survived to the time of infusion survived the experiment. Bolus injection (100,000 IU) and constant infusion of 100,000 1U/h of pro-UK or TC-UK induced no appreciable response (Table II, Fig. 8) .
A 200,000 IU loading dose of TC-UK followed by 200,000 IU/h induced modest thrombolysis (17.2%), whereas a constant infusion of 200,000 IU/h (2 mg) pro-UK without a loading dose induced highly significant (P < 0.001) thrombolysis (53.4%) compared with the TC-UK group (Fig. 8 , Table II ).
The fibrinogen concentration at the end of the infusion was less in the TC-UK group (70.4%±28) than in the pro-UK rabbits (86.5%±8.4). However, this difference was not significant (P < 0.20) (Table II) .
A fairly constant level offibrinolytic activity was maintained in the plasma ofthe animals infused with pro-UK, ranging from 20 to 40 IU/ml, which was equivalent to -40-65 IU/ml of pro-UK. In the TC-UK rabbits, the level of fibrinolytic activity in plasma was more variable and ranged from 0 to 15 IU/ml. DOGS. A bolus of 300,000 IU (1.5 mg) followed by a bolus Pro-UK 100,000 + 100,000 u/h (2) TC-UK 100, 000 + 100,000 u/h (2) of 800,000 IU (4 mg) of pro-UK induced no fibrinogen degradation. By contrast, a bolus injection of 300,000 IU TC-UK or LMW-UK induced complete fibrinogenolysis within 30 min of the injection. No detectable fibrinolysis occurred with any of the bolus injections. In three dogs treated with a constant infusion of 75,000 IU/ h pro-UK (0.75 mg), a 10-15-fold peak rise in blood radioactivity occurred. This level of blood radioactivity was consistent with a 75-100% estimated lysis ofthe thrombi (Fig. 9) . No fibrinogen degradation accompanied thrombolysis in these animals, in contrast to the LMW-UK dogs, the difference being significant (P < 0.001). (Table III) .
At a comparable infusion rate, LMW-UK gave no rise in the blood radioactivity. At a slightly higher rate of 100,000 IU/ h thrombolysis equivalent to that in the pro-UK animals occurred in three dogs but was accompanied by complete fibrinogenolysis occurring after 2-3 h of infusion. This was associated in the three animals by uncontrollable bleeding from all cut surfaces, hematuria in one dog, and bloody secretions from the airway in another. Only a little, easily controlled oozing from cut surfaces occurred in the pro-UK treated dogs.
A fairly constant level offibrinolytic activity was maintained in the plasma of the dogs infused with pro-UK, ranging from 8 to 15 IU/ml, which was equivalent to -25-50 IU/ml of pro-UK. In the LMW-UK dogs, the plasma fibrinolytic activity was HOURS Figure 9 . Radioactivity (mean and range) released into the blood of dogs embolized with 2'I-clots. The corresponding estimated percentage thrombolysis is shown. The response to saline (o), 75,000 IU/h LMW-UK (6), 75,000 IU/h pro-UK (.) and 100,000 IU/h LMW-UK (o).
either 0 or > 100 IU/ml in the defibrinated dog given the higher dose of enzyme.
HALF-LIFE OF PRO-UK. In both the rabbit and dog, -90% of the radioactivity was lost from the circulation within 5 min after injecting the '25I-pro-UK. The t1/2 of the remaining 10%
of the radioactivity was 6-7 h in both species. After bolus infusions of unlabeled pro-UK, there was a rapid, dose-related return ofblood fibrinolytic activity to base line. A bolus injection of 800,000 IU in the dog produced a plasma level of fibrinolytic activity of >100 IU/ml immediately after injection, falling to 46 IU/ml after 5 min, to 13 IU/ml after 10 min, and to 0 after 14 min. A bolus of 100,000 IU in the dog gave a plasma level of 48 IU/ml (equivalent to -70 IU pro-UK/ml) immediately after injection, falling to 0 in 5 min. The loss of fibrinolytic activity after bolus injection in the rabbit was comparably rapid. (12) also isolated UK from plasma where it appeared to be present in an inactive form, suggesting that the UK in blood may be similar to pro-UK. The physiological role ofUK in blood and its relation to tissue plasminogen activator (t-PA) is not known. However, the present findings demonstrate that pro-UK is an effective and specific activator of fibrinolysis under physiological conditions.
The pro-UK preparation used was contaminated by a small amount ofTC-UK. When the latter was inhibited by DFP treatment, a residual amidolytic activity remained, provisionally interpreted to be its intrinsic activity, which corresponded to 0.1% ofthat induced by plasmin activation ofpro-UK. The untreated pro-UK preparation had a plasmin stimulation factor of only about 10-fold (Fig. 8) , implying a 10% contamination with TC-UK. This is consistent with the electrophoretic pattern of the preparation after reduction. In the process of radiolabeling, some conversion of pro-UK to TC-UK occurred, which accounted for the more abundantly contaminated autoradiographs.
In the plasma clot-lysis experiments, the small amount of TC-UK was evidently rapidly inactivated by inhibitors, since prolonged (50 h) incubation (37°C) of the pro-UK did not induce measurable plasmin elaboration. These experiments also demonstrated the stability of pro-UK in plasma since full clotlysing capacity was retained over this period of time. Plasmin elaboration occurred only after the addition of a fibrin clot.
Under these conditions, proteolysis appeared to be confined to the clot since fibrinogen remained unchanged. Any TC-UK and plasmin released from the clot during lysis were presumably inactivated by plasma inhibitors. At higher concentrations of pro-UK than needed for complete clot lysis, fibrinogen degradation was seen, probably because the inhibitor content of the small volume of plasma used had been saturated. By contrast, in buffer, plasminogen activation by pro-UK was similar to that induced by TC-UK and occurred in the absence of fibrin. This finding implicates inhibitors in the fibrin-dependence of pro-UK activation in plasma.
In blood, alpha2-antiplasmin rapidly inactivates plasmin (13), which prevents activation of pro-UK. By contrast, plasmin bound to fibrin by its lysine binding site is unavailable for interaction with antiplasmin (14) . As a result, plasmin inactivation on the fibrin surface is delayed more than 100-fold (15) . The stability of plasmin on a clot may explain the fibrin-dependence of pro-UK activation in plasma. Plasminogen/plasmin bound to fibrin may thereby enable a cycle of mutual activation. The trigger to this chain reaction is not known but is unlikely to be t-PA since it has a plasma half-life of only 2-4 h (16) and full clot lysis occurred with pro-UK in bank plasma incubated (370C) for 50 h. Other possible triggers include the Factor XII-dependent pathway of fibrinolysis. It is also possible that the low intrinsic activity of pro-UK itself is sufficient to trigger this reaction.
Pro-UK was originally isolated from urine by affinity chromatography on fibrin-coated celite (1), the same method by which we had previously purified t-PA from blood (17) . Although fibrin celite binding of pro-UK distinguished it from TC-UK,
we have failed to demonstrate a similar difference in their fibrinclot binding. This was tested in buffered saline, plasma, and native blood (18) . It was concluded that the fibrin-specificity of pro-UK is more dependent on fibrin stabilization of plasmin activity than on its own fibrin-binding. By contrast, the t-PA in blood (17) and that purified from melanoma cells by Rijken and Collen (19) does bind tightly to fibrin. The other major contrasting property is the full enzymatic activity of the single chain form oft-PA compared with its two-chain derivative (20) . This may account for t-PA's relatively short plasma half-life of 2-4 h (13) compared with the more than 50 h for pro-UK.
Testing the thrombolytic properties ofplasminogen activators in animals is complicated by major species differences in response as illustrated by the unusual fibrin-specificity of streptokinase in the rabbit (21) . The sensitivity to UK is known to be species specific (22) and was confirmed by the broad range ofsensitivity indices obtained for human UK in the eight species tested. Interestingly, in each animal the sensitivity to human pro-UK was 5-10 times greater than to TC-UK. Species differences in sensitivity to t-PA also exist but are different, with the rabbit being quite sensitive and the dog relatively resistant (23) . Since the rabbit is especially resistant to UK (24) , its selection to compare the thrombolytic efficacy of t-PA with UK may not be appropriate (25) .
The thrombolytic effect of pro-UK in the rabbits was highly significantly greater than TC-UK at comparable doses. The total pro-UK dose given was, in fact, slightly smaller due to omission of the customary loading dose. The latter serves the function of overcoming anti-UK inhibitors that do not react with pro-UK, making a loading dose unnecessary. In this species TC-UK caused a little more fibrinogen degradation than pro-UK but the difference was not significant.
The in vivo fibrin-specificity ofpro-UK compared with TC-UK was demonstrated in the dog. Pro-UK induced virtually complete thrombolysis without loss offibrinogen. Even a massive bolus of 800,000 IU of pro-UK had no effect on the fibrinogen concentration whereas LMW-UK caused defibrinogenation after a bolus of 300,000 IU. Thrombolysis by LMW-UK was achieved at a 33% greater infusion rate than pro-UK and was accompanied by total fibrinogen depletion and uncontrollable bleeding from cut surfaces and hematuria. Only slight oozing from cut surfaces was encountered in the pro-UK-treated animals.
In conclusion, pro-UK is a zymogen form of UK with a highly selective mode of action under physiological conditions. This appears to be related to its fibrin-dependent activation mechanism. The fibrinolytic properties of pro-UK suggest that it may prove to be a fibrin-specific and effective thrombolytic agent in man, a species considerably more sensitive to the fibrinolytic effect of human UK than the rabbit or dog.
